The biotech field, specifically Alnylam Pharmaceuticals, continues to make strides. Gateway Investment Advisers LLC acquired an additional 1,222 shares of Alnylam Pharmaceuticals. Meanwhile, the company's technical benchmark exceeded the 80-plus RS rating. The second quarter financial results were released, highlighting key activities. Despite the stocks trading down by 6.7%, it delivered a robust 33% growth and set an ambitious $2.25 billion revenue target for 2025. The company's ambitious growth translated into lucrative returns, with every $1,000 invested 15 years ago now significantly more valuable. Alnylam provided full-year earnings guidance for 2025 and announced its regulatory application to the European Medicines Agency for Vutrisiran intended for the treatment of ATTR Amyloidosis with Cardiomyopathy. A Supplemental New Drug Application (sNDA) for the same medicine was also filed with the US Food and Drug Administration. Additionally, Alnylam Pharmaceuticals shared interim Phase 1 data of Nucresiran (ALN-TTRsc04), which indicated effective TTR knockdown sustained over six months following a single dose.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 18 Jan 2025 09:38:11 GMT - Rating 7 - Innovation 8 - Information 9 - Rumor -7
